COMP <GO>
KYMR vs KRYS // FORWARD P/E MULTIPLE
Kymera Therapeutics Inc. (NASDAQ) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: KYMR 5
— KRYS 5
▲ FORWARD P/E MULTIPLE LEADER: KYMR
LAST: $122.60 (+0.07%) • MKT CAP: $10.19B
forward-pe
30.4x
LAST: $324.55 (+0.97%) • MKT CAP: $9.61B
forward-pe
39.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | 16.50% | -37.90 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 53.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | 1.97% | -4.27 | KRYS | /fcf-yield <GO> |
| Operating Margin | -60.00% | 41.50% | -101.50 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 52.60% | +15.40 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 33.90% | -50.60 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.6 | 48.2 | +13.40 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.91 | +0.04 | KYMR | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 30.4x | 39.4x | -9.00 | KYMR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.19B | $9.61B | $588.0M | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | KRYS REV | KYMR GROSS % | KRYS GROSS % | KYMR FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $389.1M | 0.0% | — | -$234.3M | $188.9M |
| FY 2024 | $47.1M | $290.5M | 0.0% | — | -$207.3M | $119.2M |
| FY 2023 | $78.6M | $50.7M | — | — | -$106.4M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
KRYS // BETA 0.91